{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-016684","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.076069+00:00","generated_at":"2026-06-16T03:48:45.816710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biomea Fusion reports Q1 net loss $29.1M, cash $86.7M plus $172.5M offering; positive Phase II diabetes data","bullets":["Net loss $29.1M vs $16.4M in Q1 2022; R&D expense $24.4M (up from $11.4M).","Cash $86.7M at Mar 31, 2023; plus $172.5M gross from April offering to ≈$259M total.","COVALENT-111 Phase II Cohort 3 (100 mg): 89% of patients had HbA1c reduction, 56% had ≥1% reduction.","IND cleared for BMF-500; Phase I COVALENT-103 for FLT3-mutant acute leukemias to start enrolling.","Initial AML/ALL data from COVALENT-101 expected in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-016684","json":"https://secwatch.observer/filing/0000950170-23-016684.json","markdown":"https://secwatch.observer/filing/0000950170-23-016684.md","text":"https://secwatch.observer/filing/0000950170-23-016684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023016684/0000950170-23-016684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023016684/bmea-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T03:48:45.816710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9f25d22eb0972f6ffb9f7e073e4c7fb7b0279be","claim":"Biomea Fusion, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 2, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023016684/0000950170-23-016684-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}